RVL Pharmaceuticals Management
Management criteria checks 4/4
RVL Pharmaceuticals' CEO is Brian Markison, appointed in Jan 2016, has a tenure of 8.25 years. total yearly compensation is $525.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 2.1% of the company’s shares, worth $2.33. The average tenure of the management team and the board of directors is 8.3 years and 4.9 years respectively.
Key information
Brian Markison
Chief executive officer
US$525.0k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 8.3yrs |
| CEO ownership | 2.1% |
| Management average tenure | 8.3yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
RVL Pharmaceuticals plc (NASDAQ:RVLP) Analysts Just Cut Their EPS Forecasts Substantially
Aug 16
Analysts Just Made A Major Revision To Their RVL Pharmaceuticals plc (NASDAQ:RVLP) Revenue Forecasts
May 13RVL Pharmaceuticals plc (NASDAQ:RVLP) Doing What It Can To Lift Shares
May 12RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt
Apr 20Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?
Jan 05RVL Pharmaceuticals sees Q3 net sales of UPNEEQ for eye treatment about $10M
Oct 18RVL Pharmaceuticals: Chapter 2 - A Developing Quandary
Sep 22RVL Pharma in pact with Revision Skincare to broaden access to products
Aug 30GAAP EPS of -$0.14 beats by $0.07, revenue of $8.45M misses by $0.07M
Aug 11RVL Pharma posts preliminary 42% sales growth for eye treatment
Jul 07RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt
Jul 04RVL Pharmaceuticals: Chapter 1 Gives A Mixed Picture
Jun 15New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)
Apr 01RVL Pharmaceuticals: A Makeover For An Ugly Duckling
Mar 30Osmotica: A Different Breed Of Cat
Dec 14Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt
Aug 20Osmotica: Paring Down, Focusing On UPNEEQ
Jul 16These 4 Measures Indicate That Osmotica Pharmaceuticals (NASDAQ:OSMT) Is Using Debt Extensively
May 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$68m |
| Mar 31 2023 | n/a | n/a | -US$56m |
| Dec 31 2022 | US$525k | US$525k | -US$52m |
| Sep 30 2022 | n/a | n/a | -US$53m |
| Jun 30 2022 | n/a | n/a | -US$66m |
| Mar 31 2022 | n/a | n/a | -US$76m |
| Dec 31 2021 | US$1m | US$665k | -US$83m |
| Sep 30 2021 | n/a | n/a | -US$115m |
| Jun 30 2021 | n/a | n/a | -US$86m |
| Mar 31 2021 | n/a | n/a | -US$82m |
| Dec 31 2020 | US$4m | US$716k | -US$89m |
| Sep 30 2020 | n/a | n/a | -US$64m |
| Jun 30 2020 | n/a | n/a | -US$178m |
| Mar 31 2020 | n/a | n/a | -US$285m |
| Dec 31 2019 | US$4m | US$683k | -US$271m |
| Sep 30 2019 | n/a | n/a | -US$351m |
| Jun 30 2019 | n/a | n/a | -US$243m |
| Mar 31 2019 | n/a | n/a | -US$112m |
| Dec 31 2018 | US$1m | US$633k | -US$110m |
| Sep 30 2018 | n/a | n/a | -US$1m |
| Jun 30 2018 | n/a | n/a | -US$10m |
| Mar 31 2018 | n/a | n/a | -US$31m |
| Dec 31 2017 | US$1m | US$613k | -US$41m |
Compensation vs Market: Brian's total compensation ($USD525.00K) is about average for companies of similar size in the US market ($USD670.12K).
Compensation vs Earnings: Brian's compensation has been consistent with company performance over the past year.
CEO
Brian Markison (64 yo)
8.3yrs
Tenure
US$525,000
Compensation
Mr. Brian A. Markison has served as Chairman of the Board and Chief Executive Officer of Osmotica Pharmaceutical Corp. since 2016. Mr. Markison had been an Operating Executive and Healthcare Industry Execu...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 8.3yrs | US$525.00k | 2.1% $ 2.3 | |
| Executive VP & COO | 8.3yrs | US$367.20k | 0.45% $ 0.5 | |
| General Counsel | 10.3yrs | US$367.20k | 0.15% $ 0.2 | |
| Principal Accounting Officer | 2yrs | no data | no data | |
| Executive Vice President of Human Resources | 8.3yrs | no data | no data | |
| Secretary | no data | no data | no data |
8.3yrs
Average Tenure
52.5yo
Average Age
Experienced Management: RVLP.Q's management team is seasoned and experienced (8.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 8.3yrs | US$525.00k | 2.1% $ 2.3 | |
| Independent Director | 5.3yrs | US$234.00k | 0.045% $ 0.05 | |
| Independent Director | 1.7yrs | US$159.94k | 0.020% $ 0.02 | |
| Independent Director | 4.5yrs | US$309.10k | no data |
4.9yrs
Average Tenure
57.5yo
Average Age
Experienced Board: RVLP.Q's board of directors are considered experienced (4.9 years average tenure).